National Active Surveillance Network and Pharmacogenomics of Adverse Drug Reactions in Children
NCT00414115
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
604-875-2179
Adult Trials: 18+ Years
- Children under 19 years who have taken drugs.
- Biological parents of children who have had an ADR.
- Patients/parents who speak and understand English (except in Quebec).
- Adults (for validation of findings in children)
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Vancouver, British Columbia
| Descriptive Information | |||||||
|---|---|---|---|---|---|---|---|
| Brief Title | National Active Surveillance Network and Pharmacogenomics of Adverse Drug Reactions in Children | ||||||
| Official Title | Canadian Pharmacogenomics Network for Drug Safety | ||||||
| Brief Summary | The purpose of the study is (1) to identify and collect samples from children and adults who take drugs and have adverse drug reactions AND children and adults who take drugs and do not experience any adverse drug effects; (2) to determine if genetic differences between the two groups contribute to causing the adverse drug reactions; and (3) to develop patient specific drug dosing guidelines to prevent future adverse drug reactions. We also wish to compare the use of prescription drugs, medical and hospital services and vital statistics between BC participants who experience adverse drug reactions and those who do not. Study hypothesis: Genetic differences may contribute to patients' response to drugs and may be responsible for adverse drug reactions. | ||||||
| Detailed Description | CPNDS will identify ADR predictive markers by comparing DNA and plasma samples from patients that suffer ADRs with samples from control populations that are stratified by medication type and age. The GATC will obtain its clinical material for ADR patients mainly, from hospital-based active surveillance network across Canada's major hospitals. 1. CPNDS will examine known SNPs in candidate genes related to the ADR (i.e. drug metabolism genes, drug transporter genes, drug target genes, and other disease-specific genes or genes related to the physiological pathway of the ADR.) 2. CPNDS will discover novel ADR predictive SNPs and mutations by sequencing DNA samples from our patient cohorts. CPNDS will also genotype and sequence DNA samples from populations of controls that received the same drugs, but did not suffer ADRs; and a second population of control patients who represent a random sample of the population of known ethnic backgrounds. Novel ADR predictive SNPs and mutations will be functionally validated by pharmacokinetic approaches applied to time course analysis of drug concentrations for each specific genotype. Pharmacokinetic studies will also be used to determine the drug concentration in patients to characterize possible mechanisms of the ADR, translating into rational approaches to the choice of candidate genes to be examined in the genomic analyses. The cost-effectiveness of an ADR screening program for the prevention of ADRs in children and adults will be calculated in detailed health-economic studies. | ||||||
| Study Type | Observational | ||||||
| Study Design | Observational Model: Cohort Time Perspective: Other | ||||||
| Target Follow-Up Duration | Not Provided | ||||||
| Biospecimen | Not Provided | ||||||
| Sampling Method | Probability Sample | ||||||
| Study Population | Children under 19 years who have taken drugs and adults to replicate findings in children | ||||||
| Condition | Adverse Drug Reaction (ADR) | ||||||
| Intervention | Not Provided | ||||||
| Study Groups/Cohorts | Not Provided | ||||||
| Publications * | Carleton B, Poole R, Smith M, Leeder J, Ghannadan R, Ross C, Phillips M, Hayden M. Adverse drug reaction active surveillance: developing a national network in Canada's children's hospitals. Pharmacoepidemiol Drug Saf. 2009 Aug;18(8):713-21. doi: 10.1002/pds.1772. | ||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||||
| Recruitment Information | |||||||
| Recruitment Status | Recruiting | ||||||
| Estimated Enrollment | 7000 | ||||||
| Original Enrollment | 5000 | ||||||
| Estimated Study Completion Date | March 2023 | ||||||
| Estimated Primary Completion Date | March 2023 (Final data collection date for primary outcome measure) | ||||||
| Eligibility Criteria | Inclusion Criteria:
| ||||||
| Sex/Gender |
| ||||||
| Ages | Child, Adult, Older Adult | ||||||
| Accepts Healthy Volunteers | Yes | ||||||
| Contacts |
| ||||||
| Listed Location Countries | Canada | ||||||
| Removed Location Countries | |||||||
| Administrative Information | |||||||
| NCT Number | NCT00414115 | ||||||
| Other Study ID Numbers | H04-70358 CW Health Centre of BC W04-0138 | ||||||
| Has Data Monitoring Committee | No | ||||||
| U.S. FDA-regulated Product | Not Provided | ||||||
| IPD Sharing Statement | Not Provided | ||||||
| Responsible Party | Bruce Carleton, University of British Columbia | ||||||
| Study Sponsor | University of British Columbia | ||||||
| Collaborators |
| ||||||
| Investigators |
| ||||||
| PRS Account | University of British Columbia | ||||||
| Verification Date | November 2020 | ||||||